The utility and complications of plasma administration in cirrhotic patients undergoing minimally invasive procedures. Issue 7 (October 2021)

• Record Type: Journal Article
• Authors: Diaz, Kelly E.; Tremblay, Douglas; Ozturk, Begum; Ezaz, Ghideon; Arinsburg, Suzanne; Jhang, Jeffrey; Schiano, Thomas D.
• Is Part Of: Blood coagulation and fibrinolysis. Volume 32:Issue 7(2021)
• Publication Date: 2021-10
• Subjects: catheter placement -- cirrhosis -- coagulopathy -- plasma -- transjugular liver biopsy; Blood -- Coagulation -- Periodicals; Fibrinolysis -- Periodicals; Hemostasis -- Periodicals; Thrombosis -- Periodicals; Blood Coagulation -- Periodicals; Fibrinolysis -- Periodicals; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 612.115
• DOI: 10.1097/MBC.0000000000001072
• Languages: English
• ISSNs: 0957-5235

Abstract

Abstract : N/A: Patients with cirrhosis have coagulopathy often necessitating correction with blood products, such as plasma products (fresh frozen plasma and plasma frozen within 24 h) prior to certain invasive procedures. However, plasma administration has the potential for substantial negative adverse effects such as volume overload, transfusion-related lung injury and allergic/anaphylactic reactions. In addition, its effectiveness in preventing bleeding is similarly unclear. The purpose of this study was to determine the safety and efficacy of plasma administration in cirrhotic patients undergoing minimally invasive procedures, specifically vascular access placement, transjugular liver biopsies, renal biopsies and thoracenteses. In this retrospective cohort study, we identified patients receiving plasma products in preparation for an invasive procedure, with the primary outcomes of volume overload and bleeding. Of the 145 transfusion events that met the criteria from 2015 to 2018, the median INR decreased from 2.7 to 2.2 pre and post plasma administration and 13.8% of recipients had complications of volume overload. The cost of acquisition of plasma administered below clinically impactful doses accumulates to an estimated 19 000 dollars over this time period, not including nursing preparation or production costs. Plasma products minimally, if at all, improved laboratory values of coagulation and in some patients led to adverse effects.